Similarly, for anti-β2GPI IgG, anti-β2GPI IgM, aPS/PT IgG, and aPS/PT IgM, the percentage of positive samples was highest in APS patients but comparable in HCPs and COVID-19 patients. This evidence concerns the gene CD40LG and COVID-19.